scholarly journals Urobiome: In Sickness and in Health

2019 ◽  
Vol 7 (11) ◽  
pp. 548 ◽  
Author(s):  
Bartosz Wojciuk ◽  
Agata Salabura ◽  
Bartłomiej Grygorcewicz ◽  
Karolina Kędzierska ◽  
Kazimierz Ciechanowski ◽  
...  

The human microbiome has been proven to contribute to the human condition, both in health and in disease. The metagenomic approach based on next-generation sequencing has challenged the dogma of urine sterility. The human urobiome consists of bacteria and eukaryotic viruses as well as bacteriophages, which potentially represent the key factor. There have been several significant findings with respect to the urobiome in the context of urological disorders. Still, the research on the urobiome in chronic kidney disease and kidney transplantation remains underrepresented, as does research on the role of the virome in the urinary microbiota. In this review, we present recent findings on the urobiome with a particular emphasis on chronic kidney disease and post-kidney transplantation status. Challenges and opportunities arising from the research on the human urobiome will also be discussed.

2017 ◽  
Vol 4 (12) ◽  
pp. 1847
Author(s):  
Mahdi Mohammadian ◽  
Hamid Salehiniya ◽  
Fatemeh Allah Bakeshei ◽  
Abdollah Mohammadian-Hafshejani

Chronic kidney disease (CKD) is a public health problem known as one of the most important factors for premature death (Coresh et al., 2007; Martins et al., 2012). The disparity in the distribution of CKD is due to the socio-economic factors, gender, ethnicity and race at the global level (Norris and Nissenson, 2008; Norris and Agodoa, 2005). Roles of socio-economic conditions have been recently taken into account as a key factor in the pathway of CKD creation and expansion (Bruce et al., 2009; Nicholas et al., 2015). Several studies worldwide investigated a strong relationship between socioeconomic status and incidence of CKD complications (Crews et al., 2012; Jurkovitz et al., 2012; Saab et al., 2012).


2020 ◽  
Vol 10 (1) ◽  
pp. e78-e85 ◽  
Author(s):  
Philip J. O'Connell ◽  
Mark Brown ◽  
Tak Mao Chan ◽  
Rolando Claure-Del Granado ◽  
Simon J. Davies ◽  
...  

Objective: the present study was aimed to evaluate the role of pharmaceutical services in improving the outcome of mineral bone disorder in patients with advanced chronic kidney disease. Methodology: One hundred and twenty patients with chronic kidney disease-mineral bone disorder (CKD-MBD) screened for eligibility, seventy-six patients enrolled in the study and randomly allocated into two groups: pharmaceutical care and usual care, both groups interviewed by the pharmacist using specific questionnaire for assessing the quality of life (QoL). All the drug related problems (DRPs) including drug-drug interactions (DDIs) were recorded by the pharmacist. Blood samples were collected and utilized for analyzing the levels of vitamin D, phosphorous, calcium, albumin and parathyroid hormone at baseline and three months after. The pharmaceutical care group received all the educations about their medications and how to minimize DRPs; improve the QoL. Additionally, the pharmaceutical intervention included correcting the biochemical parameters. Results: Pharmaceutical care significantly improved patients QoL and minimized DRPs and DDIs. It was also effective in improving the biochemical parameters. Conclusion: Pharmaceutical care has a positive impact on improving the outcome of patients with CKD-MBD through attenuating DRPs, improving the biochemical parameters and the QoL.


2016 ◽  
Vol 23 (17) ◽  
pp. 1698-1707 ◽  
Author(s):  
Domenico Santoro ◽  
Vincenzo Pellicanò ◽  
Valeria Cernaro ◽  
Viviana Lacava ◽  
Antonio Lacquaniti ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document